CN1638786A - 免疫功能以及与之有关的改善 - Google Patents

免疫功能以及与之有关的改善 Download PDF

Info

Publication number
CN1638786A
CN1638786A CNA038050943A CN03805094A CN1638786A CN 1638786 A CN1638786 A CN 1638786A CN A038050943 A CNA038050943 A CN A038050943A CN 03805094 A CN03805094 A CN 03805094A CN 1638786 A CN1638786 A CN 1638786A
Authority
CN
China
Prior art keywords
per unit
unit dosage
chrysin
resveratrol
psk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA038050943A
Other languages
English (en)
Other versions
CN100579535C (zh
Inventor
迈克尔·唐纳德·法利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1638786A publication Critical patent/CN1638786A/zh
Application granted granted Critical
Publication of CN100579535C publication Critical patent/CN100579535C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种发明专利配方，用来提高身体对抗艾滋病、病毒性和传染性疾病和癌症的自然免疫功能。液体或胶囊凝胶囊片中的组合物每单位剂量含有：(a)200－600mg白杨素；(b)200－600mg Coriolus Versicolor(PSK)；(c)50－150mg 3，3′二吲哚基甲烷Dim；(d)50－150mg白藜芦醇25％；(e)50－150mg姜黄提取物95％；(f)40－140mg绿茶提取物95％；(g)20－80mg二水合栎精99％；和(h)15－75mg磷脂酰胆碱50％。有利地，每剂量单位优选地含有25mg－约150mg杨梅黄酮。

Description

免疫功能以及与之有关的改善
本发明涉及人体对抗艾滋病、病毒性和相关传染性疾病和癌症的免疫系统。
这种免疫功能是一个系统，其作用包括过量液体的吸收及其向血流中的回流，脂肪的吸收，以及最终的免疫系统功能。
免疫力是身体抵抗外来物质和细胞的能力。非特异性应答是第一道防线。高特异性应答是第二道防线，适合于具体的威胁。
根据本发明，液体或胶囊凝胶囊片(caplet)中每单位剂量的营养或药物组合物，其特征在于每单位剂量含有：
(a)200-600mg白杨素；
(b)200-600mg Coriolus Versicolor(PSK)；
(c)50-150mg 3，3’二吲哚基甲烷Dim；
(d)50-150mg白藜芦醇25％；
(e)50-150mg姜黄提取物95％；
(f)40-140mg绿茶提取物95％；
(g)20-80mg二水合栎精99％；和
(h)15-75mg磷脂酰胆碱50％。
优选地，本发明也可含有25mg-约150mg杨梅黄酮。
有利地，本发明可以包括液体或胶囊凝胶囊片中每单位剂量的营养或药物组合物，其特征在于每单位剂量含有：
(a)200-600mg白杨素；
(b)200-600mg Coriolus Versicolor(PSK)；
(c)50-150mg 3，3’二吲哚基甲烷Dim；
(d)50-150mg白藜芦醇25％；
(e)50-150mg姜黄提取物95％；
(f)40-140mg绿茶提取物95％；
(g)20-80mg二水合栎精99％；
(h)15-75mg磷脂酰胆碱50％；和
(i)25-150mg杨梅黄酮。
所有这些天然配方都含有植物化学物质，已知它们在下列所有癌细胞系中能导致细胞凋亡、细胞毒性和复制抑制。
THP-1人单核细胞白血病细胞
CaCo-2人结肠癌细胞
人白血病HL-60细胞
HLA B40-阳性乳腺癌细胞
雌激素受体阳性的MCF-7(人乳腺癌细胞系)
雌激素受体阴性的MDA-MB-468(人乳腺癌细胞)
鳞状细胞癌(SCC)(口)
雄激素敏感的LNCaP(人前列腺)
雄激素不敏感的PC-3细胞系(人前列腺)
这些植物化学物质也已经检测，发现它们对艾滋病、HIV和疱疹病毒有效。其在两个水平上起作用。一个水平是直接且正面地作用于免疫系统。这是通过提高人体自身的自然杀伤细胞的数量和功能，以及提高淋巴细胞的数量和功能实现的。由于这一原因，这可能是市场上可以获得的对抗艾滋病、癌症和病毒感染的最有效的预防剂之一。
为了提高生物利用率，植物化学物质悬浮于脂质体中。这种技术目前用于提高某些化学治疗剂的效能。它使得希望的植物化学物质能够更直接地呈递给淋巴系统。也可以用于艾滋病患者的治疗。
然而，本发明起到一种全新的作用，即在身体自然免疫功能系统内稳定并形成对抗艾滋病、病毒性传染病和癌症的增强的防御机制。
液体形式中每单位剂量的组合物以每日三次各两汤匙的正常剂量施用。除了液体形式以外，每单位药剂也可以转变为胶囊凝胶囊片，使之更容易对患者施用，以代替液体剂型。
一种发明专利配方，用来提高身体对抗艾滋病、病毒性和传染性疾病和癌症的自然免疫功能。液体或胶囊凝胶囊片中的组合物每单位剂量含有：
(a)200-600mg白杨素；
(b)200-600mg Coriolus Versicolor PSK；
(c)50-150mg 3，3’二吲哚基甲烷Dim；
(d)50-150mg白藜芦醇25％；
(e)50-150mg姜黄提取物95％；
(f)40-140mg绿荼提取物95％；
(g)20-80mg二水合栎精99％；和
(h)15-75mg磷脂酰胆碱50％。
有利地，每剂量单位优选地含有25mg-约150mg杨梅黄酮。
在本发明中，对一定数量人体试验的最初测试结果显示，在大约42-45天的短时间内病毒载量下降92-66％平均75％。
根据经验治疗的所有患者，CD4和CD8细胞大大增加。

Claims (6)

1.液体形式或胶囊凝胶囊片中每单位剂量的药物组合物或营养组合物，其特征在于每单位剂量形式含有：
(a)200-600mg白杨素；
(b)200-600mg Coriolus Versicolor PSK；
(c)50-150mg 3，3’二吲哚基甲烷Dim；
(d)50-150mg白藜芦醇25％；
(e)50-150mg姜黄提取物95％；
(f)40-140mg绿茶提取物95％；
(g)20-80mg二水合栎精99％；和
(h)15-75mg磷脂酰胆碱50％。
2.如权利要求1所述的每单位剂量的组合物，其特征在于每单位剂量还含有25mg-约150mg杨梅黄酮。
3.如权利要求1所述的液体形式或胶囊凝胶囊片中每单位剂量的组合物，其特征在于每单位剂量形式含有：
(a)400mg白杨素；
(b)400mg Coriolus Versicolor(PSK)；
(c)100mg 3，3’二吲哚基甲烷Dim；
(d)100mg白藜芦醇25％；
(e)100mg姜黄提取物95％；
(f)90mg绿茶提取物95％；
(g)50mg二水合栎精99％；和
(h)40mg磷脂酰胆碱50％。
4.如权利要求2所述的液体或胶囊凝胶囊片中每单位剂量的组合物，其特征在于每单位剂量形式含有：
(a)400mg白杨素；
(b)400mg Coriolus Versicolor(PSK)；
(c)100mg 3，3’二吲哚基甲烷Dim；
(d)100mg白藜芦醇25％；
(e)100mg姜黄提取物95％；
(f)90mg绿茶提取物95％；
(g)50mg二水合栎精99％；
(h)40mg磷脂酰胆碱50％；和
(i)100mg杨梅黄酮。
5.液体或胶囊凝胶囊片中每单位剂量的药物或营养组合物，其特征在于每单位剂量含有：
(a)200-600mg白杨素；
(b)200-600mg Coriolus Versicolor PSK；
(c)50-150mg 3，3’二吲哚基甲烷(DIM)；
(d)50-150mg白藜芦醇25％；
(e)50-150mg姜黄提取物95％；
(f)40-140mg绿茶提取物95％；
(g)20-80mg二水合栎精99％；
(h)15-75mg磷脂酰胆碱50％；
(i)25mg-约150mg杨梅黄酮。
6.液体或胶囊凝胶囊片中每单位剂量的药物组合物或营养组合物，其特征在于每单位剂量含有：
(a)400mg白杨素；
(b)400mg Coriolus Versicolor PSK；
(c)100mg 3，3’二吲哚基甲烷Dim；
(d)100mg白藜芦醇25％；
(e)100mg姜黄提取物95％；
(f)90mg绿茶提取物95％；
(g)50mg二水合栎精99％；
(h)40mg磷脂酰胆碱50％；和
(i)100mg杨梅黄酮。
CN03805094A 2003-01-09 2003-01-09 免疫功能以及与之有关的改善 Expired - Fee Related CN100579535C (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/000709 WO2004062683A1 (en) 2003-01-09 2003-01-09 Improvements in or relating to immune functions

Publications (2)

Publication Number Publication Date
CN1638786A true CN1638786A (zh) 2005-07-13
CN100579535C CN100579535C (zh) 2010-01-13

Family

ID=34885486

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03805094A Expired - Fee Related CN100579535C (zh) 2003-01-09 2003-01-09 免疫功能以及与之有关的改善

Country Status (8)

Country Link
EP (1) EP1581238B1 (zh)
JP (1) JP2006501308A (zh)
CN (1) CN100579535C (zh)
AT (1) ATE395925T1 (zh)
DE (1) DE60321227D1 (zh)
HK (1) HK1078471A1 (zh)
MX (1) MXPA04011768A (zh)
WO (1) WO2004062683A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106974904A (zh) * 2017-03-14 2017-07-25 南方医科大学 杨梅素及其衍生物的新用途和一种抗hiv感染的杀微生物剂
CN110772578A (zh) * 2019-11-11 2020-02-11 李胜 一种用于癌症防治的人体免疫力增强剂及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2381951B1 (en) * 2009-01-28 2015-12-23 Life Science Nutrition AS Compositions and methods of treating viral infections
ES2428665B1 (es) * 2012-05-04 2014-10-01 Universidad De Valladolid Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689036B2 (en) * 1995-05-10 1998-03-19 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
PL332306A1 (en) * 1996-09-20 1999-08-30 Howard Foundation Method of obtaining composition containing polyphenoles
US6238673B1 (en) * 1996-09-20 2001-05-29 The Howard Foundation Method of producing high flavonol content polyphenol compositions
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106974904A (zh) * 2017-03-14 2017-07-25 南方医科大学 杨梅素及其衍生物的新用途和一种抗hiv感染的杀微生物剂
CN106974904B (zh) * 2017-03-14 2020-07-28 南方医科大学 杨梅素及其衍生物的新用途和一种抗hiv感染的杀微生物剂
CN110772578A (zh) * 2019-11-11 2020-02-11 李胜 一种用于癌症防治的人体免疫力增强剂及其制备方法

Also Published As

Publication number Publication date
JP2006501308A (ja) 2006-01-12
MXPA04011768A (es) 2005-03-31
HK1078471A1 (en) 2006-03-17
WO2004062683A1 (en) 2004-07-29
EP1581238A1 (en) 2005-10-05
DE60321227D1 (de) 2008-07-03
CN100579535C (zh) 2010-01-13
EP1581238B1 (en) 2008-05-21
ATE395925T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
US6544564B1 (en) Cytotoxic pharmaceutical composition
Nonose et al. Oral administration of curcumin (Curcuma longa) can attenuate the neutrophil inflammatory response in zymosan-induced arthritis in rats
Lu et al. Novel anti-inflammatory and neuroprotective agents for Parkinson's disease
Ezhilarasan et al. Plant derived antioxidants and antifibrotic drugs: past, present and future
CN1638786A (zh) 免疫功能以及与之有关的改善
CN116600794A (zh) 用于治疗和预防covid-19和相关病理的川陈皮素组合物和方法
JP5118863B2 (ja) 催眠用医薬組成物
Alam et al. Bio-active compounds (curcumin, allicin and gingerol) of common spices used in Indian and south-east asian countries might protect against COVID-19 infection: a short review
JP2017533264A (ja) 抗炎症性、増殖性、保護性及び粘膜付着性の、可溶性且つ安定な医薬組成物、粘膜部位の状態を治療するためのその使用及び取得方法、並びに医薬組成物の調製のための基本医薬組成物及びその取得方法
Ramírez et al. In vivo protection against chagasic cardiomyopathy progression using trypanocidal fractions from Lippia alba (Verbenaceae) essential oils
CN1434052A (zh) 老鹳草总黄酮提取物及其在制备抗病毒药物中的用途
CN105796538A (zh) 白藜芦醇及其类似物作为hiv潜伏病毒库激活剂的应用
RU2537025C1 (ru) Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций
Koriem Cortex Uncariae: A review on pharmacology, toxicology, precautions, and dosage
Christina et al. Phaleria macrocarpa leaves extract reduce tumors growth and improve histological changes of liver and kidney on 4T1 breast cancer mice model
Elgamal Evaluation Of Curcumin And Chitosan Protective Effect On Submandibular Salivary Gland Toxicity Induced By Monosodium Glutamate In Male Albino Rats
Abdelkader et al. Rhizomatous plants: Curcuma longa and Zingiber officinale in affording immunity
Bhandary et al. The Medicinal Chemistry of Curcuma longa: A Narrative Review
RU2438688C1 (ru) Антигельминтное средство растительного происхождения
CN1883693A (zh) 一种治疗肩周炎的中药复合物
CN1078468C (zh) 叶绿素铜钠盐用于制造抗胃粘膜损伤的组合物的用途
Azhar et al. Antibacterial activity of Zingiber Officinale Roscoe extract as a potential root canal irrigation solution against Enterococcus faecalis
NEGI et al. Prevention of SARS-CoV-2 Infection with Antioxidants and Anti-inflammatory Action of Indian Spices: Light at the End of the Tunnel.
CN103142928A (zh) 骨筋口服液及其制备方法
WO2013042132A1 (en) A novel herbal formulation for the modulation of immune system of hiv infected patients and a process of preparation thereof.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078471

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078471

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100113

Termination date: 20110109